Protocol No. ARQ197-A-U303 entitled "A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects with MET Diagnostic-High Inoperable Hepatocellular Carcinoma (HCC) Treated with One Prior Systemic Therapy"

Project: Other project

StatusFinished
Effective start/end date3/22/135/1/16

Funding

  • Daiichi Sankyo: $35,511.00